摘要
Recently,metabolic(dysfunction)associated fatty liver disease(MAFLD)has been proposed as a name to replace non-alcoholic fatty liver disease(NAFLD)(1).Controversy over the name is in full swing and evidence-based debate will determine the outcome.Evidence-based medicine is predicated on rigorous scientific data,clinical experience and patient preferences.So how does MAFLD stack up?We briefly summarize the existing evidence and find that MAFLD does hold up to its promise as an advance in the terminology for the disease we all treat.
基金
This work was supported by grants from the National Natural Science Foundation of China(82070588)
High Level Creative Talents from Department of Public Health in Zhejiang Province(S2032102600032)and Project of New Century 551 Talent Nurturing in Wenzhou.
